
OBN chief executive Jon Rees steps down
pharmafile | June 24, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | OBN, jon rees, ross sommerville
UK life sciences membership organisation OBN has confirmed that its chief executive Jon Rees is stepping down in August after a decade in the role.
Rees (pictured) will continue to support the body in a senior consultant and business development capacity, and meanwhile its board has named Ross Sommerville as the interim chief executive as it looks for a more permanent replacement.
Sommerville takes leadership experience to OBN gained through global medtech organisations, and for the past 12 years was with ResMed where he led its UK and European businesses.
Under Rees’ leadership OBN grew from a University project into a diversified, financially-sustainable association delivering activities to its members, including the large life sciences investment European conference BioTrinity. More recently OBN has expanded its activities to establish itself as a voice for emerging R&D companies.
David Laskow-Pooley who is the chairman of OBN, says: “Jon’s contribution to OBN has been enormous. I wish to thank him for the energy and commitment which he has brought to the organisation and for what he has delivered for our member companies.”






